- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilar Articles for the Week of May 3
Here are the top 5 biosimilar articles for the week of May 3, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of May 3, 2021.
Number 5: Representative Carolyn B. Maloney questions the use of pharmaceutical profits to defend against biosimilar competition in recent arguments before the House Subcommittee on Antitrust, Commercial, and Administrative Law.
Number 4: Biosimilars producers reported positive sales trends for biosimilars as the pandemic wears on and said patients still are not visiting doctors in the proportions they did before the start of the health crisis in early 2020.
Number 3: Biocon Biologics reported that their first-quarter revenues were up 26%, to $275.9 million, vs the comparable year-ago quarter, driven largely by the company's biosimilars, research services, and generics businesses.
Number 2: The results of the Voltaire-X trial could persuade the FDA to authorize automatic substitution of the adalimumab biosimilar Cyltezo for its reference product (Humira), investigators believe.
Number 1: Two much-touted bills for biologics and biosimilar advancement were signed into law by President Joe Biden, but the devil is in the details, and whether they are going to have a tangible effect on biosimilar access is debatable.
To read all of these articles and more, visit centerforbiosimilars.com.
Senators Introduce Bipartisan Legislation to Protect Skinny Labeling
January 2nd 2025To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
The Top 5 Most-Read Biosimilar Articles of 2024
December 31st 2024The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, with projections indicating strong uptake in biosimilars at the expense of the originator products, despite challenges like uptake disparities and safety concerns.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Top 5 Most-Read Rheumatology Articles of 2024
December 30th 2024The top 5 rheumatology biosimilar articles of 2024 highlight significant FDA approvals, including high-concentration adalimumab and tocilizumab biosimilars, along with evidence supporting the safety and efficacy of biosimilar-to-biosimilar switching.
